Maresin 1

Maresin 1, produced by human Mφs from endogenous docosahexaenoic acid (DHA) and a specialized proresolving mediator, stimulates intracellular [Ca²⁺] and secretion. Maresin 1 possesses anti-inflammatory activity^[1][2][3]. In Vitro:Maresin 1 (MaR1, 300 nM) reduces neutrophil migration and reactive oxygen species production, besides decreasing IL-1b, TNF-a, IL-6, and INF-g production^[3]. In Vivo:Maresin 1 (MaR1) dose-dependently inhibits TRPV1 currents in neurons, blocks capsaicin (100 nM)-induced inward currents (IC₅₀=0.49 nM), and reduces both inflammation- and chemotherapy-induced neuropathic pain in mice^[2].
Maresin 1 (MaR1, 0.1, 0.3, and 1 μg/animal, e.v.) protects mice against acute DSS-induced colitis. Maresin 1 (0.3, and 1 μg/animal, e.v.) treatment markedly reduces macroscopic damage in the acute protocol of DSS-induced colitis^[3].